Genetic Diseases
Conditions
Interventions
Sponsors
Diavein SAS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient aged at least 15 years. Patients who have signed an informed consent form approved by the Ethics Committee Patients with SS, SC, Sß0 or Sß + sickle cell anaemia documented by genotype tests Patients presenting with a vaso-occlusive attack, defined as pain or tenderness evaluated over 6 on a VAS score scale, affecting at least part of the body (including the skull, spine, sternum, ribs, pelvis and/or limbs), progressing for more than 4 hours with analgesics, and that cannot be attributed to another cause.
Exclusion criteria
Exclusion criteria: Patient with a suspicion of acute chest syndrome, based on the presence of the following symptoms: chest pain and fever, or chest pain and cough, or chest pain and a feeling of shortness of breath. Patient with severe anaemia characterised by haemoglobin = 5 or showing symptoms of anemia. Patient for which either symptoms (fever, headache) or diagnostic test results lead to the suspicion of an infection. Hypothermia patient with T° =35°C Hyperthermia patient with T° > 38.5°C Patient wearing a heart pacemaker. Patient with a known history of heart failure. Women who are pregnant or breastfeeding. Any psychological state, family situation, sociological conditions or geographic locations that could hinder compliance with the study procedures or monitoring schedules.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average time spent in crisis (EVA> 2) by measuring the intensity of pain on an EVA scale in sickle cell patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Evolution of Hb concentration in the blood;Minor and moderate dose of analgesic administered to the patient. | — |
Countries
Cote Divoire
Contacts
Public ContactRenee Paule Botti
Investigator
Outcome results
None listed